TY - JOUR
T1 - Monitoring tumor response to antivascular therapy using non-contrast intravoxel incoherent motion diffusion-weighted MRI
AU - Shi, Changzheng
AU - Liu, Dexiang
AU - Xiao, Zeyu
AU - Zhang, Dong
AU - Liu, Guanfu
AU - Liu, Guanshu
AU - Chen, Hanwei
AU - Luo, Liangping
N1 - Publisher Copyright:
2017 AACR.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Antivascular therapy is a promising approach to the treatment of non–small cell lung cancer (NSCLC), where an imaging modality capable of longitudinally monitoring treatment response could provide early prediction of the outcome. In this study, we sought to investigate the feasibility of using intravoxel incoherent motion (IVIM) diffusion MRI to quantitatively assess the efficacy of the treatments of a vascular-disrupting agent CA4P or its combination with bevacizumab on experimental NSCLC tumors. CA4P caused a strong but reversible effect on tumor vasculature; all perfusion-related parameters—D*, f, fD*, and Ktrans—initially showed a decrease of 30% to 60% at 2 hours and then fully recovered to baseline on day 2 for CA4P treatment or on days 4 to 8 for CA4P + bevacizumab treatment; the diffusion coefficient in tumors decreased initially at 2 hours and then increased from day 2 to day 8. We observed a good correlation between IVIM parameters and dynamic contrast-enhanced MRI (DCE-MRI; Ktrans). We also found that the relative change in f and fD* at 2 hours correlated well with changes in tumor volume on day 8. In conclusion, our results suggest that IVIM is a promising alternative to DCE-MRI for the assessment of the change in tumor perfusion as a result of antivascular agents and can be used to predict the efficacy of antivascular therapies without the need for contrast media injection.
AB - Antivascular therapy is a promising approach to the treatment of non–small cell lung cancer (NSCLC), where an imaging modality capable of longitudinally monitoring treatment response could provide early prediction of the outcome. In this study, we sought to investigate the feasibility of using intravoxel incoherent motion (IVIM) diffusion MRI to quantitatively assess the efficacy of the treatments of a vascular-disrupting agent CA4P or its combination with bevacizumab on experimental NSCLC tumors. CA4P caused a strong but reversible effect on tumor vasculature; all perfusion-related parameters—D*, f, fD*, and Ktrans—initially showed a decrease of 30% to 60% at 2 hours and then fully recovered to baseline on day 2 for CA4P treatment or on days 4 to 8 for CA4P + bevacizumab treatment; the diffusion coefficient in tumors decreased initially at 2 hours and then increased from day 2 to day 8. We observed a good correlation between IVIM parameters and dynamic contrast-enhanced MRI (DCE-MRI; Ktrans). We also found that the relative change in f and fD* at 2 hours correlated well with changes in tumor volume on day 8. In conclusion, our results suggest that IVIM is a promising alternative to DCE-MRI for the assessment of the change in tumor perfusion as a result of antivascular agents and can be used to predict the efficacy of antivascular therapies without the need for contrast media injection.
UR - http://www.scopus.com/inward/record.url?scp=85023768316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85023768316&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-16-2499
DO - 10.1158/0008-5472.CAN-16-2499
M3 - Article
C2 - 28487383
AN - SCOPUS:85023768316
VL - 77
SP - 3491
EP - 3501
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 13
ER -